Logo image of LNSR

LENSAR INC (LNSR) Stock Fundamental Analysis

NASDAQ:LNSR - Nasdaq - US52634L1089 - Common Stock - Currency: USD

13.66  +0.08 (+0.59%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LNSR. LNSR was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While LNSR seems to be doing ok healthwise, there are quite some concerns on its profitability. LNSR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LNSR had negative earnings in the past year.
In the past year LNSR has reported a negative cash flow from operations.
LNSR had negative earnings in each of the past 5 years.
LNSR had a negative operating cash flow in each of the past 5 years.
LNSR Yearly Net Income VS EBIT VS OCF VS FCFLNSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

LNSR has a worse Return On Assets (-47.37%) than 66.49% of its industry peers.
LNSR has a Return On Equity of -168.42%. This is in the lower half of the industry: LNSR underperforms 70.74% of its industry peers.
Industry RankSector Rank
ROA -47.37%
ROE -168.42%
ROIC N/A
ROA(3y)-34.59%
ROA(5y)-31.65%
ROE(3y)-81.1%
ROE(5y)-61.69%
ROIC(3y)N/A
ROIC(5y)N/A
LNSR Yearly ROA, ROE, ROICLNSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

LNSR's Gross Margin of 48.33% is in line compared to the rest of the industry. LNSR outperforms 42.02% of its industry peers.
In the last couple of years the Gross Margin of LNSR has grown nicely.
LNSR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.25%
GM growth 5Y2.2%
LNSR Yearly Profit, Operating, Gross MarginsLNSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

6

2. Health

2.1 Basic Checks

LNSR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LNSR has more shares outstanding
Compared to 5 years ago, LNSR has more shares outstanding
LNSR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LNSR Yearly Shares OutstandingLNSR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LNSR Yearly Total Debt VS Total AssetsLNSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -0.06, we must say that LNSR is in the distress zone and has some risk of bankruptcy.
LNSR's Altman-Z score of -0.06 is in line compared to the rest of the industry. LNSR outperforms 42.02% of its industry peers.
There is no outstanding debt for LNSR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.06
ROIC/WACCN/A
WACC9.07%
LNSR Yearly LT Debt VS Equity VS FCFLNSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.80 indicates that LNSR has no problem at all paying its short term obligations.
LNSR has a Current ratio (2.80) which is comparable to the rest of the industry.
LNSR has a Quick Ratio of 2.04. This indicates that LNSR is financially healthy and has no problem in meeting its short term obligations.
LNSR has a Quick ratio of 2.04. This is comparable to the rest of the industry: LNSR outperforms 48.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.04
LNSR Yearly Current Assets VS Current LiabilitesLNSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for LNSR have decreased strongly by -206.96% in the last year.
The Revenue has grown by 26.87% in the past year. This is a very strong growth!
LNSR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.87% yearly.
EPS 1Y (TTM)-206.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1121.05%
Revenue 1Y (TTM)26.87%
Revenue growth 3Y15.79%
Revenue growth 5Y11.87%
Sales Q2Q%33.73%

3.2 Future

Based on estimates for the next years, LNSR will show a very strong growth in Earnings Per Share. The EPS will grow by 29.52% on average per year.
The Revenue is expected to grow by 32.11% on average over the next years. This is a very strong growth
EPS Next Y85.38%
EPS Next 2Y39.89%
EPS Next 3Y29.52%
EPS Next 5YN/A
Revenue Next Year31.82%
Revenue Next 2Y30.58%
Revenue Next 3Y32.11%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LNSR Yearly Revenue VS EstimatesLNSR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
LNSR Yearly EPS VS EstimatesLNSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LNSR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LNSR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LNSR Price Earnings VS Forward Price EarningsLNSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LNSR Per share dataLNSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as LNSR's earnings are expected to grow with 29.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.89%
EPS Next 3Y29.52%

More info and screens

0

5. Dividend

5.1 Amount

LNSR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LENSAR INC

NASDAQ:LNSR (5/29/2025, 2:50:58 PM)

13.66

+0.08 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners41%
Inst Owner Change11.58%
Ins Owners20.14%
Ins Owner Change6.88%
Market Cap161.05M
Analysts45.71
Price Target15.3 (12.01%)
Short Float %1.58%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-360.05%
Min EPS beat(2)-776.91%
Max EPS beat(2)56.8%
EPS beat(4)2
Avg EPS beat(4)-212%
Min EPS beat(4)-776.91%
Max EPS beat(4)56.8%
EPS beat(8)3
Avg EPS beat(8)-130.3%
EPS beat(12)7
Avg EPS beat(12)-81.62%
EPS beat(16)9
Avg EPS beat(16)-63.08%
Revenue beat(2)2
Avg Revenue beat(2)12.75%
Min Revenue beat(2)10.09%
Max Revenue beat(2)15.42%
Revenue beat(4)3
Avg Revenue beat(4)6.47%
Min Revenue beat(4)-1.61%
Max Revenue beat(4)15.42%
Revenue beat(8)4
Avg Revenue beat(8)3.2%
Revenue beat(12)6
Avg Revenue beat(12)1.08%
Revenue beat(16)10
Avg Revenue beat(16)4.15%
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.11%
EPS NY rev (1m)0%
EPS NY rev (3m)31.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.01
P/FCF N/A
P/OCF N/A
P/B 8.64
P/tB 12.85
EV/EBITDA N/A
EPS(TTM)-4.85
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS4.54
BVpS1.58
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.37%
ROE -168.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.33%
FCFM N/A
ROA(3y)-34.59%
ROA(5y)-31.65%
ROE(3y)-81.1%
ROE(5y)-61.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.25%
GM growth 5Y2.2%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.97%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.04
Altman-Z -0.06
F-Score3
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)4.73%
Cap/Depr(5y)8.26%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-206.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1121.05%
EPS Next Y85.38%
EPS Next 2Y39.89%
EPS Next 3Y29.52%
EPS Next 5YN/A
Revenue 1Y (TTM)26.87%
Revenue growth 3Y15.79%
Revenue growth 5Y11.87%
Sales Q2Q%33.73%
Revenue Next Year31.82%
Revenue Next 2Y30.58%
Revenue Next 3Y32.11%
Revenue Next 5YN/A
EBIT growth 1Y43.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.65%
EBIT Next 3Y40.8%
EBIT Next 5YN/A
FCF growth 1Y75.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.45%
OCF growth 3YN/A
OCF growth 5YN/A